1
|
10-year mortality risk in NN women
| | | |
8
|
17
|
5
|
14
|
3
|
6
|
3
|
6
|
5
|
14
|
3
|
6
|
2
|
10-year mortality real risk in those with 1–3 positive nodes
| | | |
33
|
33
|
30
|
30
|
13
|
13
|
33
|
33
|
30
|
30
|
13
|
13
|
3
|
Reduction in 10-year mortality with adjuvant therapy in NN women
| | | |
3.8
|
7.6
|
2.4
|
6.3
|
1.3
|
2.8
|
0.8
|
1.6
|
1.4
|
3.8
|
0.8
|
1.6
|
4
|
Reduction in 10-year mortality with adjuvant therapy in NP women (as would apply to the false-negative patients)
| | | |
14.2
|
14.2
|
13
|
13
|
6.1
|
6.1
|
8.1
|
8.1
|
7.5
|
7.5
|
3.4
|
3.4
|
5
|
Difference in absolute benefit between NN and NP women from chemotherapy (NP - NN)
| | | |
10.4
|
6.6
|
10.6
|
6.7
|
4.8
|
3.3
|
7.3
|
6.5
|
6.1
|
3.7
|
2.6
|
1.8
|
6
| | | | | | | | | | | | | | | | |
7
|
Unsuspected harm in a SNB-negative woman = (overall risk for missing positive axilla [AFN = FNR × ENP] × difference between benefit for NP and NN women [NP - NN]) + (harm from axillary relapse [AFN × 0.1])
|
9.7%
|
Actual % of patients with missed positive axilla (AFN = ENP × FNR)
|
1.5
|
3.4
|
1.2
|
2.9
|
1.0
|
2.4
|
1.5
|
3.4
|
1.2
|
2.9
|
1.0
|
2.4
|
8
| | |
Mortality due to axillary recurrence (AFN × 0.1)
|
0.15
|
0.34
|
0.12
|
0.29
|
0.10
|
0.24
|
0.15
|
0.34
|
0.12
|
0.29
|
0.10
|
0.24
|
9
| | |
Mortality due to no chemotherapy (AFN × [NP - NN])
|
0.15
|
0.22
|
0.12
|
0.19
|
0.05
|
0.08
|
0.11
|
0.22
|
0.07
|
0.11
|
0.03
|
0.04
|
10
| | |
Total
|
0.30
|
0.56
|
0.24
|
0.49
|
0.14
|
0.32
|
0.25
|
0.56
|
0.19
|
0.40
|
0.12
|
0.29
|
11
|
Unsuspected harm in a SNB-negative woman = (overall risk for missing positive axilla [AFN = FNR × ENP] × difference between benefit for NP and NN women [NP - NN]) + (harm from axillary relapse [AFN × 0.1])
|
20.0%
|
Actual % of patients with missed positive axilla (AFN = ENP × FNR)
|
3.0
|
7.0
|
2.4
|
6.0
|
2.0
|
5.0
|
3.0
|
7.0
|
2.4
|
6.0
|
2.0
|
5.0
|
12
| | |
Mortality due to axillary recurrence (AFN × 0.1)
|
0.30
|
0.70
|
0.24
|
0.60
|
0.20
|
0.50
|
0.30
|
0.70
|
0.24
|
0.60
|
0.20
|
0.50
|
13
| | |
Mortality due to no chemotherapy (AFN × [NP - NN])
|
0.31
|
0.46
|
0.25
|
0.40
|
0.10
|
0.17
|
0.22
|
0.46
|
0.15
|
0.22
|
0.05
|
0.09
|
14
| | |
Total
|
0.61
|
1.16
|
0.49
|
1.00
|
0.30
|
0.67
|
0.52
|
1.16
|
0.39
|
0.82
|
0.25
|
0.59
|
15
|
Unsuspected harm in a SNB-negative woman = (overall risk for missing positive axilla [AFN = FNR × ENP] × difference between benefit for NP and NN women [NP - NN]) + (harm from axillary relapse [AFN × 0.1])
|
100.0%
|
Actual % of patients with missed positive axilla (AFN = ENP × FNR)
|
15
|
35
|
12
|
30
|
10
|
25
|
15
|
35
|
12
|
30
|
10
|
25
|
16
| | |
Mortality due to axillary recurrence (AFN × 0.1)
|
1.50
|
3.50
|
1.20
|
3.00
|
1.00
|
2.50
|
1.50
|
3.50
|
1.20
|
3.00
|
1.00
|
2.50
|
17
| | |
Mortality due to no chemotherapy (AFN × [NP - NN])
|
1.56
|
2.31
|
1.27
|
2.01
|
0.48
|
0.83
|
1.10
|
2.28
|
0.73
|
1.11
|
0.26
|
0.45
|
18
| | |
Total
|
3.06
|
5.81
|
2.47
|
5.01
|
1.48
|
3.33
|
2.60
|
5.78
|
1.93
|
4.11
|
1.26
|
2.95
|